# Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem)

> **NCT04249401** · — · COMPLETED · sponsor: **Bayer** · enrollment: 134897 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Rivaroxaban (Xarelto)
- **DRUG:** Apixaban
- **DRUG:** Dabigatran
- **DRUG:** Warfarin

## Key facts

- **NCT ID:** NCT04249401
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-01
- **Primary completion:** 2023-09-30
- **Final completion:** 2023-09-30
- **Target enrollment:** 134897 (ACTUAL)
- **Last updated:** 2024-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04249401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04249401, "Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04249401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*